Table 3 Progression Free Survival and 2-year OS in IPASS Study based on EGFR mutation
Outcome | Gefitinib | Carboplatin+Paclitaxel | HR (95% CI) | P Value |
|---|---|---|---|---|
Median PFS, months | Â | Â | Â | Â |
EGFR mutation | 9.5 | 6.3 | 0.48 (0.36-0.64) | < 0.0001 |
No EGFR mutation | 1.5 | 5.5 | 2.85 (2.05-3.98) | < 0.0001 |
2-year OS, % | Â | Â | Â | Â |
EGFR mutation | 71.2 | 66.7 | 0.78 (0.50-1.20) | Not Significant |
No EGFR mutation | 42.9 | 50.6 | 1.38 (0.92-2.09) | Not Significant |